Pfizer (NYSE:PFE) Trading 0.4% Higher

Pfizer Inc. (NYSE:PFE) shares traded up 0.4% on Friday . The company traded as high as $28.77 and last traded at $28.62. 5,385,224 shares were traded during mid-day trading, a decline of 86% from the average session volume of 38,178,727 shares. The stock had previously closed at $28.51.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their price target for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Barclays upped their price target on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, August 19th. Finally, Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Stock Down 0.5 %

The stock’s 50-day moving average price is $29.05 and its two-hundred day moving average price is $28.04. The stock has a market capitalization of $160.76 billion, a PE ratio of -476.92, a P/E/G ratio of 1.02 and a beta of 0.68. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same period in the prior year, the firm posted $0.67 EPS. Pfizer’s revenue for the quarter was up 2.1% on a year-over-year basis. As a group, analysts expect that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.92%. The ex-dividend date was Friday, July 26th. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.

Institutional Trading of Pfizer

Several institutional investors have recently bought and sold shares of PFE. Olistico Wealth LLC bought a new position in Pfizer during the 2nd quarter valued at about $25,000. MFA Wealth Advisors LLC bought a new position in Pfizer during the 2nd quarter valued at about $29,000. Quarry LP bought a new position in Pfizer during the 2nd quarter valued at about $31,000. Creekmur Asset Management LLC bought a new position in Pfizer during the 4th quarter valued at about $32,000. Finally, Trivant Custom Portfolio Group LLC lifted its stake in Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.